▎ 摘　　要

NOVELTY - Hybrid material, comprises: 50-256 pts. wt. of a hydroxyl-terminated poly(amidoamine) dendrimer; 9 pts. wt. of folic acid; and 11 pts. wt. graphene oxide. The hydroxyl-terminated poly(amidoamine) dendrimer and the folic acid are chemically bound on the graphene oxide to form the hybrid material. USE - The hybrid material is useful as: a fluorescence marker; an attacking drug in photodynamic therapy (all claimed) for treating cancer; an imaging agent for fluorescence imaging; and a drug delivery system for additional therapeutic agents. Test details are described but no results given. ADVANTAGE - The hybrid material: is less toxic; and exhibits strong fluorescence emission and two photon absorption properties. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a hybrid material, comprising at least a hydroxyl-terminated fourth-generation poly(amidoamine) dendrimer and folic acid chemically bound on graphene oxide to form the hybrid material, where the hybrid material is prepared by: mixing the hydroxyl-terminated poly(amidoamine) dendrimer and the graphene oxide under stirring at a room temperature; adding N,N'-dicyclohexylcarbodiimide and 4-dimethylaminopyridine to a mixture of the hydroxyl-terminated poly(amidoamine) dendrimer and graphene oxide under stirring at the room temperature for esterification to form an intermediate graphene oxide/a hydroxyl-terminated fourth-generation poly(amidoamine) dendrimer (GO/DEN-OH) that is the hydroxyl-terminated poly(amidoamine) dendrimer bound on the graphene oxide; adding N-hydroxysuccinimide and 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride to an aqueous suspension of the intermediate GO/DEN-OH; and adding the folic acid to a mixture of N-hydroxysuccinimide, 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride and the aqueous suspension of the intermediate GO/DEN-OH under stirring at the room temperature to obtain the hybrid material.